Home Technology Medical device Medtronic Growth Highlights Gl...
Medical Device
CIO Bulletin
24 November, 2025
Medtronic records a good performance result; the medical equipment manufacturers have been able to navigate tariffs that make them change their supply chains.
The latest report by Medtronic demonstrates that even with increased pressure on tariffs, a successful medical device maker can be a profitable company. The Ireland-based company registered the highest revenue growth in over ten years without the pandemic causing its highest growth due to an increase of 9 in the sales of cardiovascular devices. The company has a facility in Galway, which is one of the major centers of research, development, and manufacturing of heart stents and this was key in the performance of the company.
In the current fiscal year, Medtronic foresees a considerable effect of tariffs but has mitigated the blow by creating different supply chains and delivering products separately directly to South America without going through the U.S. tariff remit. Such strategic actions have helped the firm increase its profit outlook by 2026 and this is an indication that the company is resilient even in the global medical equipment market.
Other industry players, such as Johnson & Johnson, Boston Scientific and Abbott, have also reduced their estimated tariff liabilities, meaning that there have been an overall flexibility in their medical device manufacture.
Ireland is experiencing its medtech ecosystem that has become stronger through over 300 companies with 48,000 professionals in the country. The country has now emerged as one of the top five medtech manufacturing countries in the world and one of the largest exporters of medical device products in Europe.
Nevertheless, there are challenges ahead. The changes in the U.S. tariff investigations, EU policy and tension on global trade may transform the future of the sector. The suggested EU regulations in favor of local production can break the existing supply chains and raise expenses, which can be dangerous to the successful Irish medtech sector.







